中文摘要：

目的评价扶正化瘀方对肝纤维化模型大鼠肝组织纤维化及活化肝星状细胞（HSC）的影响。方法64只雄性SD大鼠随机分为正常对照组、四氯化碳（CCl4）肝纤维化模型组、药物干预低剂量组和药物干预高剂量组。除正常组外，所有大鼠用CCl4复合法制备大鼠肝纤维化模型；在造模同时，药物干预组给予扶正化瘀方灌胃，1次／d，6次／周，共6周（低剂量组按0．75g／kg，高剂量组1．5g／kg）；分别在实验的第2、4、6周处死正常组、模型组及药物干预低、高剂量组大鼠各4只，收集大鼠血清及肝组织标本，测定大鼠血清ALT、AST、总胆红素（TBil）；组织标本常规石蜡包埋、切片、HE染色及Masson三重染色，采用计算机图像分析测定大鼠肝组织纤维化面积比例；测定α-平滑肌肌动蛋白（α-SMA）的积分吸光度值。组问数据比较用完全随机设计的单因素方差分析。结果2周末正常对照组、模型对照组、药物干预低、高剂量组ALT分别为（24．68±1．50）U／L、（85．33±5．68）U／L、（56．49±4．85）U／L、（36．94±5．23）U／L，4组比较，F值为98．11，差异有统计学意义；4组的AST值分别为（37．69±3．35）U／L、（112．34±7．02）U几、（82．89±5．32）U／L、（61．39±6．06）U／L，4组比较，F值为96．3l，差异有统计学意义；4组的TBil值分别为（6．70±1．10）U／L、（14．12±0．68）U／L、（10．85±0．64）U／L、（7．78±0．69）U／L，4组比较，F值为51．67，差异有统计学意义。4周末4组ALT、AST、TBil比较，F值分别为111．24、72．11、101．20，P值均〈0．05，差异均有统计学意义；6周末4组ALT、AST、TBil比较，F值分别为154．16、190．80、158．91，P值均〈0．05，差异均有统计学意义。与正常组比较，2、4、6周末模型组、扶正化瘀高、低剂量各组ALT、AST、TBil的水平均有不同程度的升高；与模型?

英文摘要：

Objective To evaluate the influence of Fuzhenghuayu decoction on fibrotic liver tissue and activated hepatic stellate cells （HSCs） using a carbon tetrachloride （CCl4）-induced liver cirrhosis rat model system. Methods Sixty-four Sprague-Dawley rats were randomly divided into the following groups： normal （non-model, non-drug intervention）, CC14 liver fibrosis model, and CC14 liver fibrosis model Fuzhenghuayu drug intervention at low dose （0.75 g/kg/d） and high dose （1.5 g/kg/d）. The drug intervention was administered via oral-gastric irrigation once daily for 6 times per week over a 6-week period. Four rats from each group were sacrificed at the end of week 2, 4, and 6 for serum and liver tissue collection. Liver fibrosis was evaluated by histology, and expression of a-smooth muscle actin （α-SMA） was determined by immunohistochemistry. Liver function was assessed by measuring levels of alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, and total bilirubin （TBil）. Between-group comparisons were made by completely random design and ANOVA with Bonferroni correction. Results At the end of weeks 2, 4 and 6, all four groups showed significantly different levels ofALT, AST, and TBil; in addition, the model group and drug intervention groups had significantly higher levels of ALT, AST, and TBil than the control group, the drug intervention groups showed significantly lower levels ofALT, AST, and TBil than the model group （P 〈 0.01 or 〈 0.05）, and the differences between the low dose and high dose groups reached statistical significance （P 〈 0.01 or 〈 0.05）. At the end of weeks 2, 4 and 6, the model group and drug intervention groups had significantly higher area ratio of liver fibrosis than the normal group （F = model： 18.68, low dose： 49.95, high dose： 82.44, P 〈 0.01）, but the two drug intervention groups had significantly less area ratio of liver fibrosis than the model group （P 〈 0.05） and the high dose group showed the most robust